Harmony Biosciences is trading at $33.03, down 4.01%, after its Q3 earnings miss.
- November 4 results: $0.81 per diluted share, below $1.00 consensus; higher royalties and a $25 million milestone charge weighed on costs and profitability.
- Revenue and WAKIX demand grew; full-year revenue guidance was reiterated, though shares remained vulnerable after the prior session’s decline.
- On November 5, a sharp broader-market and biotech sell-off added pressure; no new company-specific announcement surfaced in the search.